All In Biotech

Drug Trial Radar · NCT06421935

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Actual

Start

Aug 7, 2024

Primary completion

Feb 22, 2027

Study completion Feb 22, 2027

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
May 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.

Conditions

  • Advanced Solid Tumor

Interventions

  • M9466Drug

    Participants will be administered M9466 orally.

  • TuvusertibDrug

    Participants will be administered Tuvusertib orally.

  • Abiraterone acetateDrug

    Participants will be administered with Abiraterone acetate orally.

  • Prednisone/PrednisoloneDrug

    Participants will be administered with prednisone/prednisolone orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Module 1 Part A1 and Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs)Time frame: Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)
  2. Module 1 Part A1 and Part A2: Number of Participants with Dose Limiting Toxicity (DLT)-like eventsTime frame: Day 1 up to Day 21 of Cycle 1 (each cycle is of 21 days)
  3. Module 2 Part A1: Pharmacokinetic (PK) Plasma Concentrations of M9466Time frame: Cycle 1 Day 1 (C1D1), C1D8 and C1D15
  4. Module 2 Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs)Time frame: Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)
  5. Module 3 Part A1: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEsTime frame: Time from first treatment up to 30 days after end of study intervention
  6. Module 3 Part A1: Number of Participants with Dose Limiting Toxicity (DLT)-like EventsTime frame: Day 1 up to Day 21 of Cycle 1(each cycle is of 21 days)

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • NEXT Oncology - PARENT

    New York, New York

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Cancer Research SA

    Adelaide, Australia

  • GenesisCare North Shore (Oncology)

    St Leonards, Australia

  • Harasanshin Hospital

    Fukuoka, Japan

  • National Cancer Center Hospital East - Dept of Experimental Therapeutics

    Kashiwa-shi, Japan

  • Cancer Institute Hospital of JFCR

    Kōtoku, Japan

  • NHO Kumamoto Medical Center - Dept of Urology

    Kumamoto, Japan

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System - Division of Infectious Diseases

    Seoul, South Korea

  • Hospital HM Nou Delfos - START Barcelona

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron - Oncology Dept.

    Barcelona, Spain

  • ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia

    Barcelona, Spain

  • Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica

    Madrid, Spain

  • Hospital Universitario 12 de Octubre - Servicio de Oncologia

    Madrid, Spain

  • Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I

    Madrid, Spain

  • NEXT Madrid - Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.